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Forkhead Transcription Factor FOXO3a Is a Negative
Regulator of Angiogenic Immediate Early Gene CYR61,
Leading to Inhibition of Vascular Smooth Muscle Cell
Proliferation and Neointimal Hyperplasia
Hae-Young Lee,* Jae-Woong Chung,* Seock-Won Youn, Ju-Young Kim, Kyung-Woo Park,
Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Brahim Chaqour, Kenneth Walsh, Hyo-Soo Kim
Abstract—Cysteine-rich angiogenic protein 61 (CYR61, CCN1) is an immediate early gene expressed in vascular smooth
muscle cells (VSMCs) on growth factor stimulation, and its expression has been suggested to be associated with
postangioplasty restenosis. The forkhead transcription factors are reported to play various roles in cellular proliferation,
apoptosis, and even adaptation to cellular stress. We hypothesized that the forkhead transcription factor FOXO3a may
regulate CYR61 expression in VSMCs and investigated the CYR61-modulating effect of FOXO3a in the process of
vascular response to vasoactive signals and vascular injury. To evaluate the effect of FOXO3a on CYR61 expression,
rat VSMCs were infected with adenoviral vectors expressing constitutively active FOXO3a (Ad-TM-FOXO3a).
Constitutively active FOXO3a gene transduction suppressed CYR61 expression. Luciferase assay with the deletion
constructs of the forkhead factor binding motif in CYR61 promoter region, which resulted in a significant decrease in
luciferase expression compared with the intact construct, and chromatin immunoprecipitation analysis confirmed
transcriptional regulation of CYR61 by FOXO3a. Serum and angiotensin II rapidly induced CYR61 expression, which
was significantly reduced by Ad-TM-FOXO3a. Reduction of VSMC proliferation and migration associated with
FOXO3a activation was significantly reversed by cotransfection of adenoviral vector expressing CYR61, whereas
apoptosis induction by FOXO3a was not influenced. In a rat balloon carotid arterial injury model, CYR61 was rapidly
induced in VSMCs in the early stage of injury and remained elevated until 14 days, which was suppressed by
Ad-TM-FOXO3a transfection. After 14 days, there was a significant reduction in neointima by FOXO3a transduction
compared with the control group (0.060.02 versus 0.200.07 mm2, P0.01). Such reduction of neointimal
hyperplasia by Ad-TM-FOXO3a was reversed by CYR61 replenishment. These data suggest that FOXO3a is a negative
transcription factor of CYR61 and that suppression of CYR61 is among several mechanisms by which FOXO3a inhibits
VSMC proliferation and neointimal hyperplasia. (Circ Res. 2007;100:372-380.)
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Vascular smooth muscle cell (VSMC) proliferation andmigration are characteristic features of various vascular
pathologies, such as atherosclerosis and neointimal hyperpla-
sia after vascular intervention.1 Vasoactive growth factors
including angiotensin II and mechanical stress are known to
be involved in these processes.2 Despite the recent advances
in strategies to control restenosis, the regulatory mechanism
has not been fully defined yet. Therefore, elucidation of
possible key molecules involved in the pathophysiology of
VSMC proliferation and migration following various stimuli
may help controlling many vasculopathic conditions.
Cysteine-rich angiogenic protein 61 (CYR61, CCN1) is a
cysteine-rich heparin binding protein that belongs to the
novel CCN gene family.3 CYR61 was originally cloned as an
immediate early gene expressed in fibroblasts after growth
factor stimulation,4 and its expression has been reported to be
associated with vascular restenosis, angiogenesis, and tumor
growth.5,6 CYR61 was also reported to be expressed in
VSMCs of atheromatous plaques, where its expression was
regulated by angiotensin II.7,8
During investigation of CYR61, we found that CYR61
contains the forkhead factor binding motif AAAGCAAACA9
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in its promoter region. This was interesting, because forkhead
transcription factors are emerging as key players, under
regulation of Akt, in roles ranging from cellular proliferation,
migration, apoptosis, and even adaptation to cellular stress.10
Moreover, previous studies by our group11 and others12 have
suggested a potential role of FOXO3a, the main forkhead
transcription factor expressed in VSMCs, in preventing neo-
intimal hyperplasia by cell cycle arrest and apoptosis
induction.
The presence of the forkhead factor binding sequences in
its promoter region, and its observed function in VSMCs,
allowed the hypothesis that CYR61 might be regulated by
FOXO3a. In this study, we tested this hypothesis and inves-
tigated the modulating effect of CYR61 by FOXO3a in the
process of vascular response to vasoactive signals such as
angiotensin II and vascular injury.
Materials and Methods
VSMC Culture, Gene Transfer Using Adenoviral
Vectors, and Pharmacological Stimulation
Primary cultures of VSMCs were prepared from thoracic aortas of
adult male Sprague–Dawley rats as previously described.13 Six- to
7-passage VSMCs were incubated at 37°C in DMEM containing
10% FBS (Cambrex) with 1% antibiotic/antimycotic solution
(GIBCO BRL).
To evaluate the role of CYR61, adenovirus vector expressing
CYR61 was used.14 In terms of FOXO3a, an adenoviral vector
expressing constitutively active FOXO3a (Ad-TM-FOXO3a) was
used.15 Briefly, Ad-TM-FOXO3a was constructed by replacing 3
phosphorylation sites, Thr32, Ser253, and Ser315, with alanine
residues, a process that prevented phosphorylation by Akt. For
blocking experiments, an adenoviral vector expressing dominant-
negative form (Ad-DN-FOXO3a), the transactivation domain of
which was deleted from the C terminus, or an adenoviral vector
containing antisense FOXO3a cDNA was used. As a control, an
adenoviral vector expressing green fluorescent protein (Ad-GFP)
was used.
For gene transduction, VSMCs were infected with indicated
adenoviral vectors at 50 multiplicities of infection (mois) for 24
hours and reached a concentration with 90% transfection effi-
ciency, as shown in our previous report.11 For pharmacological
stimulation, angiotensin II (Sigma, A9525) was used with a concen-
tration of 107 mol/L.
RT-PCR and Immunoblot Analysis
Changes in RNA expression of CYR61 were determined by RT-PCR
as previously described.16 Primers used were as follows: forward
primer: 5-TCT CGT TGC TGC TCA TGA AAT T-3; reverse
primer: 5-TAG AGT GGG TAC ATC AAA GCT TCA G-3. Total
RNA was isolated by the TRIzol method (Invitrogen) and reverse
transcribed using the reverse transcription system (Promega), and
cDNA was amplified with CYR61 and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).
Immunoblot analysis was performed by modification of the
procedures described previously.17 The primary antibodies used
were as follows: anti-FOXO3a (rabbit polyclonal IgG, Upstate
Biotechnology, 1:1000), anti-hemagglutinin (HA) (Roche Applied
Science, 1:500), and anti-CYR61 (Santa Cruz Biotechnology,
1:500). As secondary antibody, anti-mouse IgG horseradish peroxi-
dase (Promega) or anti-rabbit IgG HRP (Promega) was used at a
dilution of 1:2000. Immunoblots were quantified using the chemilu-
minescent detection reagents ECL (Amersham).
Luciferase Promoter Activity Assay
Because the putative forkhead binding motif AAAGCAAACA9
exists from 760 to 751 in the promoter sequences of CYR61,18
the promoter region from 1093 to 209 upstream of translation
start site (ATG) was isolated from human genomic DNA and
subcloned into pGL3 basic luciferase expression vector (LUC)
(Promega) at the KpnI/XhoI site to create a pGL3-CYR61-LUC
(forward: 5-cgg gta cc-TAA AGT GGG AAC CTC CA-3; reverse:
5-ccg ctc gag-TCT CGC TCG CGG TCT GCC-3). And a deletion
mutant was constructed as pGL3-CYR61-LUC plasmid vector
where the forkhead binding motif was deleted (from 565 to 209
upstream of ATG; forward: 5-cgg gta cc-CTT CCC AAC ATA
AGT CG-3; reverse: 5-ccg ctc gag-TCT CGC TCG CGG TCT
GCC-3) (Figure 1D). A control plasmid expressing -galactosidase
was also transfected to serve as a reference and to control for the
transfection efficiency in each experiment. After adenoviral infec-
tion, cells were incubated with 200 L/well of reporter lysis buffer,
and lysates were mixed with the luciferase substrate reagent. The
absorbency was determined by a fluorometer (Lumi-Scint; Bioscan
Inc), corrected for -galactosidase activity determined by a standard
assay (Promega) and reported as the relative activity compared with
the control cells.
Chromatin Immunoprecipitation Assay
A chromatin immunoprecipitation assay was performed with a
commercially available kit (Upstate Biotechnology) following the
instructions of the manufacturer. Antibodies for HA and FOXO3a
were used for immunoprecipitation of the DNA fragments. The DNA
fragments were analyzed by PCR with primers specific for the
CYR61 promoter (forward: 5-CAG ATA ACT TGC CTC TCA
CC-3; reverse: 5-TAC GAC TTA TGT TGG GAA GG-3).
Cell Viability Assay
Cell viability was measured using the WST-1 assay (Roche Molec-
ular Biochemicals) according to the instructions of the manufacturer.
VSMCs were seeded in 96-well plates at 2104 cells per well in
DMEM (100 L). After serum starvation for 24 hours, VSMCs were
transfected with indicated adenoviral vectors (50 mois) for 24 hours.
At the end of the incubation period, 10 L of WST-1 was added and
incubated for 4 hours at 37°C. Absorbency was measured using an
ELISA reader at 440 nm.
Cell Proliferation and Apoptosis Assay
Cell proliferation and apoptosis were quantified by fluorescence-
activated cell sorting. After infection with adenoviral vectors at 50
mois for 24 hours, cells were harvested, fixed, and analyzed by flow
cytometry (Becton-Dickinson). For proliferation evaluation, histo-
grams of DNA contents were analyzed using Modfit LT software
(Verity Software) to characterize population fractions in each phase
of the cell cycle. Apoptosis was determined by DNA fragmentation
assessed by measuring the hypodiploid DNA contents.
Cell Migration Assay
To investigate the role of CYR61 on VSMC migration, we evaluated
the effect of the supernatant, which was harvested from the culture
dish of VSMCs transduced with indicated adenoviral vectors, on
VSMC migration using the scratch-wound migration assay as de-
scribed previously.19 In brief, VSMCs for the scratch assay were
cultured to confluence on glass coverslips in DMEM with 10% FBS.
Another set of VSMCs for supernatant harvest were cultured in
6-well plates. For supernatant collection, VSMCs in the 6-well plates
were transfected with indicated adenoviral vectors (50 mois) for 24
hours, then 1 mL of the supernatant from each culture plate was
collected. For the scratch assay, after scratching with a cell scraper
to make the wound area, the collected supernatant was applied to
VSMCs on the coverslips and incubated for 96 hours. The migration
distance was quantified using Image-Pro 4.5 (Particle Engineering
Research Center, University of Florida, Gainesville).
Rat Carotid Artery Balloon Denudation Injury
Fifteen adult male Sprague–Dawley rats weighing from 400 to 500 g
(Daehan Biolink Co) were anesthetized with a combination anes-
thetic (ketamine, 70 mg/kg; xylazine, 7 mg/kg IP; Daehan Biolink
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Co, Seoul, Korea). Balloon injury was performed in the common
carotid artery by a 2-French catheter as previously described.11 After
balloon injury, viral infusion mixtures with 5108 plaque-forming
units of indicated adenoviral vectors diluted to a total volume of 50
L were instilled into the arterial segment that was isolated by
vascular clamps and incubated for 30 minutes.
Morphometric Analysis
The vessels were harvested on days 3 and 14 after balloon injury, as
previously described.20 The extent of neointima formation was
quantified by computed planimetry of stained sections. The cross-
sectional areas of the blood vessel layers, including the lumen area,
intimal area, and medial area, were quantified at 3 different sections
(proximal, middle, and distal; n12) by using Image-Pro Plus
Analyzer version 4.5 (MediaCybernetics). The intima-to-media ra-
tios were calculated from the mean of these determinations.
Immunohistochemical Staining
Immunohistochemistry was performed as previously described.20 To
detect proliferating cells, immunohistochemical staining against
proliferating cell nuclear antigen (PCNA) were performed.21 Prolif-
eration was assessed by quantifying the percentage of PCNA-
positive cells against total nucleated cells in 4 different sectors per
tissue section (n6).
Detection of apoptotic cells was also performed using the terminal
deoxynucleotidyl transferase-mediated dUTP nick endlabeling
(TUNEL) method, with minor modifications.22 Apoptosis was quan-
tified by counting the percentage of TUNEL-positive cells against
total nucleated cells in 4 different sectors per tissue section (n6).
Statistics
All data are presented as meanSD. Comparisons between groups
were performed using the Mann–Whitney U test because of small
numbers. A probability value of less than 0.05 was considered
statistically significant.
Results
FOXO3a Suppresses CYR61 Expression in
Cultured Rat VSMCs
Efficient transduction of constitutively active FOXO3a gene
was confirmed by detecting HA, which was tagged onto the
viral construct. The activation of FOXO3a suppressed the
expression of CYR61, which was almost completely reversed
by Ad-DN-FOXO3a (Figure 1A).
Next, we evaluated serial expression of CYR61 and phos-
phorylated (thus inactivated) native FOXO3a following se-
Figure 1. FOXO3a suppresses CYR61 expression in cultured rat VSMCs. A, Immunoblot analysis of a rat VSMC 24 hours after gene
delivery. FOXO3a activation suppressed CYR61 expression, which was reversed by Ad-DN-FOXO3a cotransfection. B, Serial immuno-
blot analysis of CYR61 and phosphorylated (thus inactivated) native FOXO3a following serum (20% FBS) stimulation. C, Serial immuno-
blot analysis of CYR61 protein expression after adenoviral gene transfection. D, Sequence alignment of FOXO3a binding motif in
CYR61 promoter region. Two types of plasmid vectors containing luciferase reporter gene were constructed as follows; pGL3-CYR61-
LUC, plasmid with full sequence of CYR61 promoter; pGL3-CYR61-LUC, plasmid with FOXO3a binding motif deleted. E, Relative
luciferase activity compared with the control. Luciferase activity was normalized by -galactosidase activity, which was cotransfected
to normalize the plasmid transfection efficiency. The data represent meansSE (N9). F, Chromatin immunoprecipitation assay
of CYR61.
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rum (FBS 20%) stimulation. Phosphorylation of FOXO3a
was found to increase from 30 minutes and to peak at 1 hour
after serum stimulation without change in total amount of
FOXO3a. And CYR61 expression was found to increase from
one hour and to reach its peak at two hours, the expression
pattern of which was temporally well correlated with the
change in FOXO3a phosphorylation (Figure 1B).
Then, we evaluated the modulation of CYR61 expression
by FOXO3a. With serum stimulation, expression of CYR61
was swiftly increased, which was significantly reduced in
TM-FOXO3a–transduced cells compared with the control
(RT-PCR in Figure IA in the online data supplement, avail-
able at http://circres.ahajournals.org; immunoblot in Figure
1C).
Finally, to confirm negative regulation of CYR61 by
FOXO3a, we performed a promoter assay using a construct
(pGL3-CYR61-LUC) in which the luciferase reporter gene is
driven by the CYR61 promoter18 and a construct (pGL3-
CYR61-LUC) in which the 5-forkhead binding motif was
deleted (Figure 1D). VSMCs transfected with each CYR61
promoter construct were subsequently infected with Ad-TM-
FOXO3a and assayed for luciferase activity. Ad-TM-
FOXO3a transfection significantly suppressed the serum-
induced luciferase activity driven by the CYR61 promoter in
the pGL3-CYR61-LUC construct (luciferase activity,
0.430.07 in Ad-TM-FOXO3a–transfected VSMCs, versus
10 in Ad-GFP-transfected group, n9, P0.01). Such
inhibitory effect of FOXO3a was not observed when fork-
head binding motif was deleted out of the promoter region of
CYR61 gene as in the pGL3-CYR61-LUC construct
(1.020.09, P0.42) (Figure 1E). The chromatin immuno-
precipitation analysis also confirmed the transcriptional reg-
ulation of CYR61 by FOXO3a (Figure 1F).
FOXO3a Decreased VSMC Viability: Effect of
CYR61 Suppression on Cell Cycle Arrest
Because we previously reported FOXO3a reduced VSMC
viability through apoptosis induction and cell cycle arrest,11
we investigated which aspect of CYR61 suppression contrib-
uted to the effect of FOXO3a activation. VSMCs were either
transfected with Ad-TM-FOXO3a alone or cotransfected
with Ad-CYR61 and cultured for 24 hours. We found that
VSMCs transfected with Ad-TM-FOXO3a showed signifi-
cant detachment from the culture plate and nuclear conden-
sations consistent with apoptosis (Figure 2B), which were
remarkably reduced by cotransfection with Ad-CYR61 (Fig-
ure 2D). Quantification of cell viability also showed that
FOXO3a activation significantly reduced VSMC viability
(cell viability relative to control (%), 46.411.1, versus
10012.2, n3, P0.05), which was also significantly
reversed by cotransfection with Ad-CYR61 (71.28.2%,
n3, P0.05 compared with Ad-TM-FOXO3a group, Figure
Figure 2. FOXO3a decreased VSMC viability: effect of CYR61 suppression on cell viability. A through D, Microscopic findings of
VSMCs at 24 hours after transfection with 50 mois of indicated adenoviral vectors. The inset shows a magnified nucleus. A, VSMCs
transfected with Ad-GFP; B, with Ad-TM-FOXO3a; C, cotransfected with Ad-TM-FOXO3a and Ad-DN-FOXO3a; D, cotransfected with
Ad-TM-FOXO3a and Ad-CYR61. Magnification 200. E, WST-1 assay evaluating VSMC viability at 24 hours after adenoviral transfec-
tion. Bar graph illustrates cell viability of each group compared with the control (null treatment). F, Apoptotic fluorescence-activated cell
sorting analysis measuring the hypodiploid DNA contents, showing significantly increased apoptotic fraction in the TM-FOXO3a–trans-
fected group. Results are expressed as the meanSEM. *P0.05 compared with the control (n6).
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2E). Interestingly, we found Ad-CYR61 transfection alone
increased viable cell count even compared with the control
(135.416.6%, n3, P0.05).
Next, we evaluated the role of CYR61 in apoptosis by
apoptotic fluorescence-activated cell sorting analysis.
FOXO3a activation significantly increased apoptotic fraction
(35.71.1% versus 5.90.5% in control, Figure 2F). How-
ever, Ad-CYR61 transfection did not show any significant
effect on apoptosis either alone or when cotransfected with
Ad-TM-FOXO3a.
Then, we evaluated the contributing role of CYR61 in
cell proliferation. CYR61 transduction significantly prop-
agated the cell cycle and increased the percentage of cells
in the S phase either alone (40.02.1 for Ad-CYR61
versus 24.00.9 for the control, Ad-GFP, P0.05) or
when cotransfected with Ad-TM-FOXO3a (33.32.0%
versus 25.21.2% for Ad-TM-FOXO3a, P0.05) (supple-
mental Table I).
Taken together, these data suggest that CYR61 suppression
by FOXO3a activation contributed to the cell cycle arrest,
although it did not contribute to apoptosis induction.
FOXO3a Blocks Angiotensin II–Induced
CYR61 Expression
Angiotensin II is known to induce CYR61,7 and we investi-
gated whether FOXO3a suppressed CYR61 expression even
in a stimulated condition. On angiotensin II stimulation,
CYR61 was rapidly induced from 30 minutes and peaked at
2 hours without change in the amount of either total or
phosphorylated FOXO3a, indicating that CYR61 induction
by angiotensin II is FOXO3a independent (Figure 3A).
However, CYR61 induction by angiotensin II was signifi-
cantly attenuated by TM-FOXO3a transduction in mRNA
levels (supplemental Figure IB), as well as in protein levels
(Figure 3B), suggesting that CYR61 expression was regulated
by at least 2 different signal pathways, angiotensin II and
FOXO3a.
Next, to confirm the regulation of CYR61 by FOXO3a, we
made in vivo experiment by delivering adenoviral vectors
containing TM-FOXO3a, antisense FOXO3a, or the control
GFP to rat aortic rings. The gene transduction efficiency,
which was measured as the percentage of cells positive for
HA (which was tagged to the adenoviral vector), was
Figure 3. FOXO3a blocked angiotensin II–induced CYR61 expression. A, Serial immunoblot analysis of CYR61, phosphorylated (thus
inactivated) native FOXO3a and total native FOXO3a after angiotensin II (107 mol/L) stimulation. B, Serial immunoblot analysis of
CYR61 protein at 2, 4, and 6 hours after angiotensin II stimulation. C, Corresponding immunohistochemistry of FOXO3a and CYR61 2
hours after angiotensin II stimulation in rat aorta that were pretransfected with Ad-GFP (left), Ad-TM-FOXO3a (middle), and
Ad-antisense-FOXO3a (right), respectively. Effective transfection of Ad-TM-FOXO3a and Ad-GFP to rat aorta was confirmed by staining
for HA, whereas Ad-antisense-FOXO3a does not contain sequences for HA.
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41.44.3% (n5, Figure 3C, top). We incubated the aortic
rings for 2 hours in DMEM with angiotensin II (107 mol/L)
ex vivo. In the control vessel, the endogenous expression
levels of FOXO3a were low and angiotensin II significantly
induced CYR61. In Ad-TM-FOXO3a transfected blood ves-
sels, however, large amounts of FOXO3a were expressed and
CYR61 expression was significantly suppressed, even after
angiotensin II stimulation. Finally, in Ad-antisense-
FOXO3a–transfected blood vessels, the endogenous
FOXO3a decreased and CYR61 expression increased more
than the control vessel (Figure 3C).
FOXO3a Decreased VSMC Migration: Effect of
CYR61 Suppression
Increased VSMC chemotaxis is another component causing
neointimal hyperplasia.23 We evaluated the role of FOXO3a
and CYR61 in VSMC migration by the scratch-wound assay.
To evaluate the effect of secreted CYR61, we used superna-
tant harvested from the culture dish of VSMCs transduced
with indicated adenoviral vectors. Supernatant from Ad-TM-
FOXO3a transfected VSMCs significantly decreased VSMC
migration compared with the control, which was nearly
completely reversed by cotransfection with Ad-CYR61 (Fig-
ure 4A and 4B). We also observed that supernatant from
Ad-CYR61–transfected VSMCs significantly enhanced
VSMC migration, even compared with the control, suggest-
ing that CYR61 suppression contributed to decreased VSMC
migration by FOXO3a activation.
FOXO3a Blocks CYR61 Expression After Balloon
Injury in Rat Carotid Artery
We investigated the role of FOXO3a activation in CYR61
expression after balloon injury. We delivered the control
vectors, Ad-GFP, or Ad-TM-FOXO3a to rat carotid arteries
immediately after balloon injury and evaluated CYR61 ex-
pression (Figure 5A). From day 3, CYR61 began to accumu-
late in media, and at day 14, CYR61 markedly accumulated,
thus being detectable both in the media and in the prolifer-
ating neointima of the control vessels. Conversely, in TM-
FOXO3a–transduced blood vessels, CYR61 expression was
remarkably suppressed, even after balloon-injury, accompa-
nied by remarkably less neointimal growth (Figure 5A).
Then, we obtained total cell lysates from rat carotid artery and
quantified CYR61 expression by tissue immunoblot, of which
patterns were well correlated with those observed in immu-
nohistochemistry (Figure 5B).
FOXO3a Activation Inhibits Neointimal
Hyperplasia, Which Was Reversed by
CYR61 Replenishment
Morphometric analysis at 14 days after balloon injury in rat
carotid artery revealed that FOXO3a activation resulted in a
significantly reduced neointimal area (0.060.02 versus
0.200.07 mm2, n12, P0.01), whereas there was no
significant difference in medial area (0.170.03 versus
0.160.03 mm2, n12, P0.27) compared with the control
group (supplemental Figure IC). As a result, FOXO3a acti-
vation led to a significantly lower intima-to-media ratio
(1.260.42 versus 0.410.20, P0.01) and a greater lumen
area (0.250.08 versus 0.310.06 mm2, P0.01) compared
with the control (Figure 6A, middle).
Conversely, when Ad-CYR61 was cotransfected with Ad-
TM-FOXO3a, reduction in neointimal hyperplasia was sig-
nificantly reversed near to the control level, suggesting
CYR61 suppression contributed to reduction in neointimal
hyperplasia by FOXO3a activation (Figure 6A, right).
Figure 4. FOXO3a decreased VSMC migration: effect of CYR61 suppression. A, Scratch-wound migration assay. Microscopic findings
of VSMCs at 96 hours after applied supernatant collected from culture dish of indicated adenoviral vector–transfected VSMCs in the
presence either of 20% FBS (top panels) or of angiotensin II (107 mol/L). Magnification, 100. B, Bar graph illustrates migrating dis-
tance. *P0.05.
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Then, we evaluated the role of CYR61 suppression by
FOXO3a activation in apoptosis after balloon injury. TUNEL
staining was performed at 3 and 14 days after balloon injury.
Although only a few TUNEL-positive cells were observed at
14 days (data not shown), enough TUNEL-positive cells for
comparison were observed at 3 days (Figure 6B). The
apoptotic activity of VSMCs was higher in TM-FOXO3a–
transfected group than the control group (33.09.7 versus
66.010.7, P0.05; Figure 6B, middle). However, CYR61
replenishment did not exert significant effect on apoptosis
(54.816.7, P0.20; Figure 6B, right).
Next, we evaluated the contributing role of CYR61 sup-
pression in VSMC proliferation by PCNA staining. PCNA-
positive cells were markedly reduced in TM-FOXO3a–trans-
duced group 14 days after balloon injury (Figure 6C, middle).
The proliferative index (calculated as the fraction of positive
cells among total nucleated cells) was significantly lower in
the Ad-TM-FOXO3a group compared with the control
(15.03.9 versus 36.25.9, P0.05), whereas CYR61 re-
plenishment significantly reversed it (28.37.5, P0.01
compared with Ad-TM-FOXO3a group) (Figure 6C, right),
suggesting that CYR61 suppression significantly contributed
to reduced VSMC proliferation by FOXO3a activation.
Discussion
The present study demonstrates that FOXO3a is a negative
transcriptional regulator of CYR61. FOXO3a activation sig-
nificantly suppressed either serum- or angiotensin II–induced
CYR61 expression in VSMCs. CYR61 suppression contrib-
uted to the effect of FOXO3a on reduction of VSMC
proliferation and migration, resulting in reduction of neoin-
timal hyperplasia. These data suggest that regulation of
CYR61 may be a novel mechanism by which FOXO3a
controls the vascular proliferative response to stimuli.
VSMC proliferation and migration are characteristic fea-
tures of various vascular diseases, such as atherosclerosis and
neointimal hyperplasia after vascular intervention. FOXO3a
is a member of the forkhead transcription factor family,
which has been shown to play an important role in cell cycle
arrest and apoptosis of various cancer cell lines,24,25 fibro-
blasts,10 endothelial cells,15 and VSMCs.26 In VSMCs, we
previously showed that FOXO3a activation led to apoptosis
and cell cycle arrest, thus inhibiting neointimal hyperplasia
via p27Kip1 upregulation.11 Although p27Kip1 upregulation was
suggested to contribute to cell cycle arrest by forkhead
transcription factors in the various cell lines mentioned
above, it is unlikely that this is the only mechanism behind
the actions of forkhead transcription factors. Considering the
existence of many downstream molecules of forkhead tran-
scription factor, it is more likely that other mechanisms may
exist.
CYR61 is observed in VSMCs of arterial walls during
embryonic development27 and in arteriosclerotic arteries.7
CYR61 was reported to be associated with tissue responses to
injury, such as bone fracture repair,28 liver regeneration,29 and
granulation tissue formation during wound healing.30 In
addition, CYR61 was found to be highly expressed in the
neointima of the balloon injured artery in rats31 and in
primates.5 All of these findings suggest that CYR61 could be
a potential target in neointimal hyperplasia. Despite several
potential binding motifs of transcription factors, such as
nuclear factor B, cAMP response element–binding protein/
JUN, or activator protein-1 in the CYR61 promoter region,18
and several physical or chemical stimuli reported to induce
CYR61 expression,32 the upstream signaling pathways of
CYR61, apart from c-Jun N-terminal kinase14 and early
growth response-1,33 have not been discovered yet. Because
CYR61 was found to have forkhead binding motif in its
promoter region, we investigated the role of FOXO3a in
CYR61 expression and found that FOXO3a is a negative
transcriptional regulator of CYR61. Because, forkhead tran-
scription factors are mainly regulated by Akt,10 we performed
experiments evaluating CYR61 expression in the presence of
dominant negative Akt to clarify the role of Akt in CYR61
expression (supplemental Figure ID). Induction of CYR61
expression by serum or angiotensin II was significantly
blocked by dominant-negative Akt gene transduction, sug-
gesting that Akt mediates CYR61 expression in response to
growth factors. However, the inhibitory effect of dominant-
negative Akt on CYR61 expression was completely abolished
Figure 5. FOXO3a blocks CYR61 expression after balloon injury in rat carotid artery. A, Immunohistochemical staining showing
increased expression of CYR61 at days 3 and 14 after balloon injury (left). The induction of CYR61 was blocked by FOXO3a-TM gene
transfer both at day 3 and day 14 (right). B, Immunoblot confirming efficient delivery of FOXO3a-TM transgene (top). The induction of
CYR61 after balloon injury was significantly decreased by FOXO3a-TM gene transfer both at day 3 and day 14 compared with control
vessels (middle).
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by cotransfection of adenovirus containing dominant-
negative FOXO3a construct, indicating that the mechanism of
dominant-negative Akt to blocking CYR61 induction is
through FOXO3a activation and that Akt indirectly regulates
CYR61 via inhibition of FOXO3a. Thus, Akt-FOXO3a path-
way is the upstream regulator (Akt is positive, whereas
FOXO3a is negative) of CYR61 expression. To the best of
our knowledge, this is the first report to link the regulation of
CYR61 expression with the Akt/FOXO3a axis. We think that
this regulation is specific for CYR61 among various CCN
family members, because we observed that connective tissue
growth factor did not have a FOXO binding element in its
promoter region and that its expression was not affected by
FOXO3a (data not shown).
Although Ad-CYR61–transfected VSMCs showed more
proliferation than the control group in our experiments,
CYR61 has not been reported to have an intrinsic mitogenic
effect, only a synergistic effect, with other mitogenic growth
factors in fibroblasts34 and in endothelial cells.35 However,
our results did not seem discrepant with respect to previous
reports, because we evaluated cell proliferation in the pres-
ence of growth stimulating condition such as serum or
balloon injury. Furthermore, consistent with the previous
report observed in endothelial cells,6 CYR61 was found to
increase VSMC migration, which might contribute to the
process of neointimal hyperplasia observed in this report.
Finally, it is possible that 2 regulatory mechanisms in
VSMCs by FOXO3a, p27Kip1 upregulation and CYR61 sup-
pression, might actually be linked with each other. CYR61 is
implicated to regulate p27Kip1 expression through integrins
such as v3 in breast cancer or hepatocellular carcinoma
cells.29,36 And connective tissue growth factor, another CCN
family member, was reported to reduce p27Kip1 expression.37
Therefore, upregulation of p27Kip1 by FOXO3a activation
might actually be a secondary finding of CYR61 suppression.
However, because p27Kip1 also has a FOXO3a binding motif
in its promoter region,9 thus being potentially regulated by
FOXO3a at the transcription level, we cannot make any
conclusions regarding the relation between the 2 downstream
molecules of FOXO3a, p27Kip1 and CYR61, at this time.
Figure 6. FOXO3a activation inhibits neointimal hyperplasia, which was reversed by CYR61 replenishment. A, Hematoxylin and eosin
staining of arteries at 14 days after balloon injury and gene delivery. FOXO3a activation resulted in a significantly reduced neointimal
area. This effect was near completely reversed by cotransfection of Ad-CYR61 with Ad-TM-FOXO3a. Magnification, 100 (top) and
400 (bottom). Bar graph illustrates intima/media ratio at 14 days after gene delivery. *P0.05 compared with the Ad-GFP, #P0.05
compared with the Ad-TM-FOXO3a (n12). B, TUNEL staining to detect apoptotic cells at day 3. Magnification, 400. Bar graph illus-
trates TUNEL index. *P0.05 compared with the Ad-GFP (n6). C, Immunohistochemical staining against PCNA at days 14. Magnifica-
tion, 200. Bar graph illustrates PCNA index, *P0.05 compared with the Ad-GFP, #P0.05 compared with Ad-TM-FOXO3a (n6).
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In summary, FOXO3a is a novel negative regulator of
CYR61. CYR61 suppression contributed to reduction of
neointimal hyperplasia by FOXO3a activation through de-
creased proliferation and possibly through reduction in mi-
gration of VSMCs. These findings offer new insights into the
role of FOXO3a in the regulation of CYR61 and CYR61-
dependent response after vessel injury.
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In an article by Lee et al (Circ Res. 2007;100:372-380), the authors regrettably supplied an
incorrectly loaded gel for tubulin for Figure 3 panel A. The corrected figure appears here.
Figure 3. FOXO3a blocked angiotensin II–induced CYR61 expression. A, Serial immunoblot analysis of CYR61, phosphorylated (thus
inactivated) native FOXO3a and total native FOXO3a after angiotensin II (107 mol/L) stimulation. B, Serial immunoblot analysis of
CYR61 protein at 2, 4, and 6 hours after angiotensin II stimulation. C, Corresponding immunohistochemistry of FOXO3a and CYR61 2
hours after angiotensin II stimulation in rat aorta that were pretransfected with Ad-GFP (left), Ad-TM-FOXO3a (middle), and
Ad-antisense-FOXO3a (right), respectively. Effective transfection of Ad-TM-FOXO3a and Ad-GFP to rat aorta was confirmed by staining
for HA, whereas Ad-antisense-FOXO3a does not contain sequences for HA.
(Circ Res. 2007;101:e1.)
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Supplemental Table I. FACS analysis of the cell cycle showing a typical profile of 
G0/G1 cell-cycle arrest in the TM-FOXO3a transfected group, in contrast to cell cycle 
propagation in the CYR61 group. Results are expressed as the mean ± SE of a 
representative experiment, performed in triplicate wells (* p < 0.05, n = 3). 
 
% of cells Ad-GFP Ad-CYR61 Ad-TM-FOXO3a Ad-TM-FOXO3a 
+ Ad-CYR61 
G1 68.0 ± 2.5 47.1 ± 1.7* 71.2 ± 1.0 68.0 ± 2.5 
S 24.0 ± 0.9 40.0 ± 2.1* 25.2 ± 1.2 33.3 ± 2.0** 
G2 + M 8.0 ± 0.7 13.3 ± 0.9 3.6 ± 0.5 11.8 ± 1.0** 
* P < 0.05 compared with the control, Ad-GFP group. 
** P < 0.05 compared with Ad-TM-FOXO3a group. 
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